ANXA2
ATC code L01
ATC code V09
ATC code V10
Abagovomab
Abemaciclib
Abituzumab
Acalabrutinib
Actinium-225
Adagrasib
Adecatumumab
Adipotide
Adrenergic
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
Alpha particle
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Antibody
Antibody-dependent cell-mediated cytotoxicity
Antigen
Antineoplastic
Apoptosis
Asciminib
Ascrinvacumab
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
B cell
Balstilimab
Baricitinib
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Bermekimab
Beta particle
Beta radiation
Bevacizumab
Binimetinib
Biogen Idec
Bismuth-213
Bivatuzumab mertansine
Blinatumomab
Bosutinib
Botensilimab
Brentuximab vedotin
Brigatinib
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carotuximab
Catumaxomab
Cediranib
Cemiplimab
Ceritinib
Cetuximab
ChEMBL
Chelator
ChemSpider
Chemotherapy
Chimeric antibody
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Complement-dependent cytotoxicity
Conatumumab
Copanlisib
Cosibelimab
Crizotinib
DTPA
Dabrafenib
Dacetuzumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
Dysprosium-165
EML4
Ecromeximab
Edrecolomab
Elotuzumab
Elranatamab
Emactuzumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erbium-169
Erdafitinib
Erlotinib
Ertumaxomab
Etaracizumab
European Medicines Agency
Everolimus
Exotoxin
Farletuzumab
Fedratinib
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
First-line therapy
Flanvotumab
Flotetuzumab
Follicular lymphoma
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Gamma camera
Ganitumab
Gefitinib
Gemtuzumab ozogamicin
Generic drug
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
Gold-198
HER2/neu
Hedgehog signaling pathway
Humanized antibody
Ibritumomab tiuxetan (data page)
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Immunoglobulin G
Inavolisib
Indatuximab ravtansine
Indium-111
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
Intetumumab
Intravenous
Iobenguane
Iodine-131
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Isotope
Istiratumab
Janus kinase
KEGG
KRAS
Labetuzumab
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Lexatumumab
Lifastuzumab vedotin
Lilotomab
Lintuzumab
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lumretuzumab
Lutetium-177
Lutetium (177Lu) oxodotreotide
Lymphatic system
Lymphoid
Lymphoma
Lymphoproliferative disorder
MEN1
MTOR inhibitor
Mapatumumab
Margetuximab
Marketing authorization
Masitinib
Matuzumab
Methyl
Midostaurin
Milatuzumab
Minretumomab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Mosunetuzumab
Mouse
Moxetumomab pasudotox
Myeloid
Nacolomab tafenatox
Naptumomab estafenatox
Narnatumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nesvacumab
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-Hodgkin's lymphoma
Non-receptor tyrosine kinase
OSTI (identifier)
Obinutuzumab
Ocaratuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Onartuzumab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otlertuzumab
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Palliative care
Panitumumab
Parsaclisib
Parsatuzumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Pertuzumab
Pexidartinib
Phases of clinical research
Phosphorus-32
Pi3K inhibitor
Pinatuzumab vedotin
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Prescription drug
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radioimmunotherapy
Radionuclide
Radiopharmacology
Radium-223
Radium chloride
Radotinib
Radretumab
Ramucirumab
Receptor tyrosine kinase
Refractory disease
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Retifanlimab
Revumenib
Rhenium-186
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Rituximab
Robatumumab
Rociletinib
Rosmantuzumab
Route of administration
Rovalpituzumab tesirine
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Samarium-153
Samarium (153Sm) lexidronam
Selpercatinib
Selumetinib
Semaxanib
Seribantumab
Serplulimab
Sibrotuzumab
Siltuximab
Simtuzumab
Sirolimus
Sofituzumab vedotin
Solitomab
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Stem cell
Strontium-89
Sugemalimab
Sunitinib
Tafasitamab
Talquetamab
Taplitumomab paptox
Tarextumab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Technetium (99mTc) arcitumomab
Technetium (99mTc) nofetumomab merpentan
Technetium (99mTc) pintumomab
Technetium (99mTc) votumumab
Teclistamab
Temsirolimus
Tenatumomab
Tepotinib
Teprotumumab
Tigatuzumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Toripalimab
Tositumomab
Tovetumab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trifunctional antibody
Trilaciclib
Tucatinib
Tucotuzumab celmoleukin
Tyrosine kinase inhibitor
Ublituximab
Unique Ingredient Identifier
VEGF receptors
Vandetanib
Vandortuzumab vedotin
Vantictumab
Vanucizumab
Vascular endothelial growth factor
Vascular endothelial growth factor A
Veltuzumab
Vemurafenib
Venetoclax
Vismodegib
Vorsetuzumab mafodotin
WHO Model List of Essential Medicines
Yttrium-90
Yttrium (90Y) clivatuzumab tetraxetan
Yttrium (90Y) tacatuzumab tetraxetan
Zalutumumab
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab